Cardiovascular comorbidities are associated with dermatomyositis: A cross-sectional study in the All of Us Research Program - 11/04/24
Doi : 10.1016/j.jaad.2023.12.037
Jill T. Shah, BA a, Keya T. Shah, DO b, Daniel R. Mazori, MD a, c, Avrom S. Caplan, MD a, c, Emily Hejazi, MD a, c, Michael S. Garshick, MD, MS a, c, d, Alisa N. Femia, MD a, c, ⁎ 
a NYU Grossman School of Medicine, New York, New York
b Department of Medicine, NYU Langone Hospital–Long Island, Mineola, New York
c The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, NYU Langone Health, New York, New York
d Center for the Prevention of Cardiovascular Disease, The Leon H. Charney Division of Cardiology, Department of Medicine, New York University Langone Health, New York, New York
∗Correspondence to: Alisa N. Femia, MD, The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, NYU Langone Health, 222 E 41st St, 16th Floor, New York, NY 10017The Ronald O. Perelman Department of DermatologyNYU Grossman School of MedicineNYU Langone Health222 E 41st St16th FloorNew YorkNY10017
Key words : atrial fibrillation, cardiovascular disease, chronic kidney disease, comorbidity, coronary artery disease, dermatomyositis, epidemiology, heart failure, heart valve diseases, hyperlipidemia, hypertension, idiopathic inflammatory myopathy, myocardial infarction, stroke, type 2 diabetes, venous thromboembolism
| Funding sources: Author Jill T. Shah is supported by the National Center for Advancing Translational Sciences (NCATS, National Institutes of Health Grant Award Number UL1TR001445). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The All of Us Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2; 1 OT2; 1 OT2; 1 OT2; 1 OT2; 1 OT2 OD 026552; 1 OT2; 1 OT2; 1 OT2; 1 OT2; IAA #: AOD 16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and Research Center: 5 U2C; Biobank: 1 U24; The Participant Center: U24; Participant Technology Systems Center: 1 U24; Communications and Engagement: 3 OT2; 3 OT2; and Community Partners: 1 OT2; 3 OT2; 1 OT2; 1 OT2. |
|
| Previous presentations: The data from this study have not been previously published. Preliminary data from this study were presented as an oral presentation at ACR Convergence 2022 in Philadelphia, PA, November 14, 2022. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Not applicable for nonhuman subjects research. |
© 2023
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 90 - N° 5
P. 1013-1016 - mai 2024 Retour au numéro
Article précédent
- HIV and mpox: Evaluation of clinical course and outcomes from an international dermatologic registry
- Alexis G. Strahan, Cristina Galvan Casas, Sonya Prasad, Lucinda Claire Fuller, Klint Peebles, Andrea Carugno, Kieron S. Leslie, Joanna L. Harp, Teodora Pumnea, Devon E. McMahon, Misha Rosenbach, Janet E. Lubov, Geoffrey Chen, Ann M. Pacheco, Lindy P. Fox, Allen McMillen, Henry W. Lim, Alexander J. Stratigos, Terrence A. Cronin, Mark D. Kaufmann, George J. Hruza, Lars E. French, Esther E. Freeman
- Epidemiology of acne and rosacea: A worldwide global study
- Jean-Hilaire Saurat, Bruno Halioua, Catherine Baissac, Nuria Perez Cullell, Yaron Ben Hayoun, Marketa Saint Aroman, Charles Taieb, Charbel Skayem
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?